All Pathways
Hematology & OncologyEmergency

Anticoagulation Reversal for Major Bleeding (ISTH 2025)

Anticoagulation Reversal for Major Bleeding (ISTH 2025): Major Bleeding on Anticoagulant → Identify Anticoagulant → Warfarin (VKA) → Supportive Care (Al...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Major Bleeding on Anticoagulant

    Life-threatening or critical site bleeding requiring reversal

    1. Decision

      Identify Anticoagulant

      Which anticoagulant is the patient taking?

      1. Action

        Warfarin (VKA)

        Vitamin K antagonist reversal

        • Check INR
        • 4-Factor PCC 25-50 units/kg (based on INR)
        • Vitamin K 10mg IV slow infusion
        • Recheck INR in 30 min
        • Target INR <1.5
        1. Action

          Supportive Care (All Patients)

          Standard hemorrhage management

          • Hold anticoagulant
          • IV access, type and screen
          • Transfuse PRBCs for hemodynamic instability
          • Consider platelets if plt <50k
          • Local hemostatic measures
          • Maintain normothermia
          1. Decision

            Bleeding Site

            Location-specific considerations

            1. Warning

              Intracranial Hemorrhage

              Most urgent - rapid reversal critical

              • Door-to-reversal time critical
              • Target SBP <140 mmHg
              • Neurosurgery consultation
              • Repeat CT in 6 hours
              • ICU admission
              1. Action

                Reassess Response

                Check hemostasis and labs

                • Clinical bleeding assessment
                • Repeat coagulation studies
                • Consider re-dosing if ongoing bleeding
                • Plan anticoagulation resumption timing
                1. Outcome

                  Bleeding Controlled

                  Plan for anticoagulation resumption based on indication

            2. Action

              GI Hemorrhage

              Endoscopy when stable

              • IV PPI (pantoprazole 80mg bolus)
              • Gastroenterology consultation
              • Endoscopy within 24h (or emergent if unstable)
              • Transfuse to Hgb >7 (>8 if CAD)
            3. Action

              Other Major Bleeding

              Muscle, retroperitoneal, etc.

              • Imaging to characterize
              • Surgical/IR consultation as needed
              • Embolization if appropriate
              • Compartment syndrome monitoring
      2. Action

        Dabigatran

        Direct thrombin inhibitor reversal

        • Idarucizumab 5g IV (2x2.5g vials)
        • Full reversal within minutes
        • Can re-dose if needed
        • If unavailable: 4F-PCC 50 units/kg
        • Hemodialysis removes ~60% in 2-3h
      3. Action

        Factor Xa Inhibitors

        Apixaban, rivaroxaban, edoxaban

        • Andexanet alfa if available:
        • Low dose: 400mg bolus + 4mg/min x2h
        • High dose: 800mg bolus + 8mg/min x2h
        • If unavailable: 4F-PCC 50 units/kg
        • TXA 1g IV as adjunct

Guideline Source

Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Specific reversal agents may not be available at all centers
  • DOAC levels may not be immediately available
  • Cost considerations may influence reversal agent choice
  • Does not cover all anticoagulants (e.g., fondaparinux)

Applicable Regions

USEUGlobal

EU: Both specific reversal agents available

US: Andexanet alfa FDA-approved; idarucizumab available

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?

The Anticoagulation Reversal for Major Bleeding (ISTH 2025) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

What guideline is the Anticoagulation Reversal for Major Bleeding (ISTH 2025) based on?

This algorithm is based on Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH (DOI: 10.1016/j.jtha.2024.07.009).

What are the limitations of the Anticoagulation Reversal for Major Bleeding (ISTH 2025)?

Known limitations include: Specific reversal agents may not be available at all centers; DOAC levels may not be immediately available; Cost considerations may influence reversal agent choice; Does not cover all anticoagulants (e.g., fondaparinux). Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Anticoagulation Reversal for Major Bleeding (ISTH 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free